跳至主要内容
临床试验/ITMCTR2100004716
ITMCTR2100004716已完成2 期

''Highly exposed Chinese herbal medicine'' combined with apatinib as maintenance treatment following first-line or second-line chemotherapy for extensive-stage small-cell lung cancer: A single-arm

The First Affiliated Hospital of Anhui Medical University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 70(—)
性别
All

入选标准

  • The inclusion criteria were as follows:
  • 1) with small-cell lung cancer (extensive stage);
  • 2) aged between 18 and 70 years;
  • 3) with at least one measurable lesion (according to the CT/MRI evaluation, the maximum diameter of the tumor was >10 mm), according to the RECIST1.1 criteria;
  • 4) had already undergone 4-6 cycles of first-line or second-line chemotherapy, and were in the status of SD;
  • 5) with the ECOG score of 0-2 points.

排除标准

  • 1) those treated with other anti-angiogenesis drugs;
  • 2) allergic to apatinib;
  • 3) could not tolerate long-term Chinese herbal medicine treatment;
  • 4) accompanied with cardiovascular diseases (such as heart diseases or uncontrolled hypertension) or hematological diseases;
  • 5) with liver or renal insufficiency;
  • 6) with severe psychological disorders and could not adhere to the treatment;
  • 7) with poor compliance and high risk of loss to follow up;
  • 8) with hemorrhagic tendency;
  • 9) underwent major surgeries within 28 d before participating in this study;
  • 10) with perforation or abdominal fistula within 28 d before participating in this study.

研究者

相似试验